Baseline demographics and characteristics of patients receiving uproleselan
| Characteristic . | All doses . | 10 mg/kg . |
|---|---|---|
| R/R (n = 66) . | Newly diagnosed patients age ≥60 y (n = 25) . | |
| Sex | ||
| Male | 41 (62) | 14 (56) |
| Female | 25 (38) | 11 (44) |
| Age, y | 59.0 (26-84) | 67.0 (60-79) |
| AML type | ||
| Primary refractory | 22 (33) | — |
| 1 induction regimen | 17/22 (77) | — |
| ≥2 induction regimens | 5/22 (23) | — |
| Relapsed | 44 (67) | — |
| Duration of remission, mo | ||
| ≤6 | 18 (41) | — |
| ≤12 | 33 (75) | — |
| Prior induction regimens, n | ||
| 1 | 44 (67) | — |
| ≥2 | 22 (33) | — |
| Prior hematopoietic stem cell transplantation | 12 (18) | |
| De novo or secondary AML | ||
| De novo | 51 (77) | 12 (48) |
| Secondary | 15 (23) | 13 (52) |
| MDS | 7 (11) | 10 (40) |
| Therapy related | 1 (2) | 1 (4) |
| Other | 7 (11) | 2 (8) |
| ELN risk category | ||
| Favorable | 7 (11) | 3 (12) |
| Intermediate | 11 (17) | 7 (28) |
| Unfavorable | 33 (50) | 12 (48) |
| Unknown | 15 (23) | 3 (12) |
| SWOG risk category | ||
| Favorable | 1 (2) | 1 (4) |
| Intermediate | 24 (36) | 16 (64) |
| Unfavorable | 39 (59) | 8 (32) |
| Unknown | 2 (4) | 0 |
| Characteristic . | All doses . | 10 mg/kg . |
|---|---|---|
| R/R (n = 66) . | Newly diagnosed patients age ≥60 y (n = 25) . | |
| Sex | ||
| Male | 41 (62) | 14 (56) |
| Female | 25 (38) | 11 (44) |
| Age, y | 59.0 (26-84) | 67.0 (60-79) |
| AML type | ||
| Primary refractory | 22 (33) | — |
| 1 induction regimen | 17/22 (77) | — |
| ≥2 induction regimens | 5/22 (23) | — |
| Relapsed | 44 (67) | — |
| Duration of remission, mo | ||
| ≤6 | 18 (41) | — |
| ≤12 | 33 (75) | — |
| Prior induction regimens, n | ||
| 1 | 44 (67) | — |
| ≥2 | 22 (33) | — |
| Prior hematopoietic stem cell transplantation | 12 (18) | |
| De novo or secondary AML | ||
| De novo | 51 (77) | 12 (48) |
| Secondary | 15 (23) | 13 (52) |
| MDS | 7 (11) | 10 (40) |
| Therapy related | 1 (2) | 1 (4) |
| Other | 7 (11) | 2 (8) |
| ELN risk category | ||
| Favorable | 7 (11) | 3 (12) |
| Intermediate | 11 (17) | 7 (28) |
| Unfavorable | 33 (50) | 12 (48) |
| Unknown | 15 (23) | 3 (12) |
| SWOG risk category | ||
| Favorable | 1 (2) | 1 (4) |
| Intermediate | 24 (36) | 16 (64) |
| Unfavorable | 39 (59) | 8 (32) |
| Unknown | 2 (4) | 0 |
Data are presented as n (%), n/N (%), or median (range).
ELN, European LeukemiaNet; MDS, myelodysplastic syndrome; mo, months; SWOG, Southwest Oncology Group.